Join
Live feed
·
PRReleasevia Quantisnow
G1 Therapeutics Inc. logo

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)

ByQuantisnow·Wall Street's wire, on your screen.
GTHX· G1 Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GTHX (G1 Therapeutics Inc.) and more on Quantisnow.